InflaRx's Covid antibody receives FDA authorization for critically ill patients.
InflaRx has announced that it has enough supply ready to treat several thousand patients with its Covid-19 antibody, Gohibic, which was cleared for use in critically ill adults within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation. The drug will likely have a five-figure price tag, according to CEO Niels Riedemann. Following talks with payers, Riedemann said Gohibic’s list price will likely be a five-digit figure, “and it will not have a 1 as first figure,” he added.